Langerhans Cell Histiocytosis with Good Response to Low-Dose Imatinib: Case Report and Literature Review

Langerhans cell histiocytosis (LCH) is a rare neoplastic disease characterized by infiltration of histiocytes and dendritic cells into body organs. While treatment is better established in pediatrics, there is still no consensus on therapy in the adult population. Imatinib has shown promising result...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdulgayoom, Mohammed, Mudawi, Deena, Lengyel, Zsolt, Abo Samra, Hayan, Alshurafa, Awni, Yassin, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355039/
https://www.ncbi.nlm.nih.gov/pubmed/37476563
http://dx.doi.org/10.1159/000531230
Descripción
Sumario:Langerhans cell histiocytosis (LCH) is a rare neoplastic disease characterized by infiltration of histiocytes and dendritic cells into body organs. While treatment is better established in pediatrics, there is still no consensus on therapy in the adult population. Imatinib has shown promising results in some case reports and a small clinical trial. We present here a fifty-nine-year-old patient with LCH in the lung, liver, and bone who responded well to an imatinib dose of 100 mg daily. Her symptoms improved within 3 months of treatment, and subsequent positron emission tomography-computed tomography (PET/CT) showed resolution of 18F-fluorodeoxyglucose (FDG)-avid lesions.

Ejemplares similares